Key facts
- Ukko’s last known valuation is $82.0M (Jan 2021).
- It has raised $104.7M; the latest was Later Stage VC ($45.0M) in Jan 2026.
- Notable investors include Khosla Ventures, Western Technology Investment, OurCrowd, Slow Ventures, Innovation Endeavors — 21 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 21 names
- ·Watchlist + deal alerts for Ukko
- ·The full record, as it builds
Funding rounds
No funding rounds for Ukko are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ukko
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2016
- Employees
- 62
- Website
- ukko.us/
- Ownership
- Privately Held (backing)
Ukko doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ukko shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ukko in its N-PORT filings yet. We sweep new filings monthly.